Table 1

Patient characteristics (n = 528)

≤65 years (n = 116)

66-70 years (n = 144)

71-75 years (n = 158)

>75 years (n = 110)

significant difference


patient age, years

mean ± SD; median

62 ± 4; 63

68 ± 2; 68

73 ± 2; 73

78 ± 2; 77

all comparisons (p < 0.01)


prostate volume, cc

mean ± SD; median

42 ± 20; 35

44 ± 20; 39

45 ± 23; 40

46 ± 21; 42

-


PSA<10 ng/mL,

n (%)

66 (57)

93 (65)

95 (60)

55 (50)

66-70 vs. >75 years (p < 0.05)


biopsy Gleason score <7; n (%)

72 (62)

90 (63)

98 (62)

55 (50)

66-70 vs. >75 years (p < 0.05)


prior hormonal therapy; n (%)

46 (40)

50 (35)

55 (35)

41 (37)

-


comorbidities;

n (%)

56 (48)

95 (66)

108 (68)

69 (63)

≤65 vs. 66-70/71-75/>75 years (p < 0.05)


hypertension;

n (%)

24 (21)

44 (31)

53 (34)

27 (25)

≤65 vs. 71-75 years (p < 0.05)


coronary heart disease;

n (%)

17 (15)

29 (20)

43 (27)

30 (27)

≤65 vs. 71-75/>75 years (p < 0.05)


diabetes;

n (%)

13 (11)

16 (11)

17 (11)

16 (15)

-


COPD;

n (%)

7 (6)

13 (9)

17 (11)

12 (11)

-


CCI<5/5/>5;

n (%)

86/17/13 (74/15/11)

69/49/26

(48/34/18)

0/85/73

(0/54/46)

0/47/63

(0/43/57)

for all (p < 0.01), with exception 71-75 vs. >75


SD: standard deviation; PSA: prostate specific antigen; COPD: chronic obstructive pulmonary disease; CCI: Charlson Comotbidity Index

Pinkawa et al. BMC Cancer 2009 9:296   doi:10.1186/1471-2407-9-296

Open Data